facebook_pixel

Equity News

News 7 December 2016
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
Sun Pharma: Possibility Of A Negative Halol Report Brings Opportunities

Sun Pharma: Possibility Of A Negative Halol Report Brings Opportunities

India’s Sun Pharmaceutical has fallen more than 20% in value since August and right now all depends on the Halol Report. The FDA has produced a 14 page report that could list potential violations of the agency’s manufacturing guidelines   The report, called a Form 483, is currently under review and will be available by […]

FIND OUT MORE

News 6 December 2016
BLUE PHOENIX FINANCIALS PREMIUM CONTENT Not a member? Join Now!
6 Major Reasons We Are Bullish On Johnson & Johnson

6 Major Reasons We Are Bullish On Johnson & Johnson

6 Major Reasons We Are Bullish On Johnson & Johnson. Johnson & Johnson has offered more than $27 billion to Buy Actelion, Europe’s biggest Biotech. Bloomberg reports that negotiations are continuing and J&J has been given access to Actelion’s financial details. The stake of Jean-Paul and Martine Clozel, who founded Actelion, has now surged to […]

FIND OUT MORE